Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2024 06:20 ET | Source: Bleichmar Fonti & Auld

RPD INVESTIGATION NEWS: Rapid7, Inc. (Nasdaq:RPD) Investors are Notified to Contact BFA Law about Inquiry into the Company’s Purchase Price

Shareholders of Rapid7 are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
July 03, 2024 06:18 ET | Source: Bleichmar Fonti & Auld

RPD ACQUISITION REVIEW: BFA Law Alerts Rapid7, Inc. (Nasdaq:RPD) Shareholders to Contact Us about Investigation into the Company’s Acquisition Price

Shareholders of Rapid7 are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
July 01, 2024 08:11 ET | Source: Bleichmar Fonti & Auld

RPD INVESTIGATION NOTIFICATION: BFA Law Notifies Rapid7, Inc. (Nasdaq:RPD) Investors that it is Investigating the Potential Acquisition, and Urges Shareholders to Contact Us

Shareholders of Rapid7 are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
June 29, 2024 06:40 ET | Source: Bleichmar Fonti & Auld

RPD INVESTIGATION NOTICE: BFA Law Alerts Rapid7, Inc. (Nasdaq:RPD) Investors that it is Investigating the Potential Acquisition, and Urges Shareholders to Contact the Firm

Shareholders of Rapid7 are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
June 27, 2024 16:45 ET | Source: Bleichmar Fonti & Auld

RAPID7 ALERT: BFA Law is Investigating a Potential Transaction between Rapid7, Inc. (Nasdaq:RPD) and Cannae Holdings, Shareholders are Encouraged to Contact the Firm

Shareholders of Rapid7 are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
April 07, 2022 10:00 ET | Source: Oncotelic Therapeutics, Inc.

Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today. Dear Fellow...